menu
    • menu
    [{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"KBP Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Labcorp Drug Development \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"Labcorp Drug Development \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"KBP Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Labcorp Drug Development \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"Labcorp Drug Development \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"KBP Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Labcorp Drug Development \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"Labcorp Drug Development \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"KBP Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Labcorp Drug Development \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"Labcorp Drug Development \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"Wellmarker Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"WM-S1-030","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Labcorp Drug Development \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"Labcorp Drug Development \/ Covance"},{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"HC-5404","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Labcorp Drug Development \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"Labcorp Drug Development \/ Covance"},{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"HC-7366-K","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Immediate Releasse Capsule","sponsorNew":"Labcorp Drug Development \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"Labcorp Drug Development \/ Covance"},{"orgOrder":0,"company":"Labcorp Drug Development","sponsor":"Enterome","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Labcorp Drug Development","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Labcorp Drug Development \/ Covance, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Labcorp Drug Development \/ Covance, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Labcorp Drug Development

    Menu

    Labcorp Drug Development

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EO2401,Nivolumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Enterome

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enterome Completes Patient Enrollment Of Phase 2 ROSALIE Study Evaluating Its Lead Immunotherapy, EO2401, In R...

                            Details : EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer.

                            Brand Name : EO2401

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 12, 2022

                            Lead Product(s) : EO2401,Nivolumab,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Enterome

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366-K

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : HiberCell

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

                            Details : The first-in-human Phase 1a/b clinical trial, designed to establish maximum tolerated dose, while evaluating safety and tolerability, and to establish recommended Phase 2 dose for HC-7366, selective, orally bioavailable modulator of GNC2 in patients with...

                            Brand Name : HC-7366

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 24, 2022

                            Lead Product(s) : HC-7366-K

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : HiberCell

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-5404

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : HiberCell

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

                            Details : The primary endpoints are to establish HC-5404-FU’s Maximum Tolerated Dose (MTD) and to monitor its safety and tolerability in patients with selected, advanced solid tumors.

                            Brand Name : HC-5404-FU

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2021

                            Lead Product(s) : HC-5404

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : HiberCell

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WM-S1-030

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Wellmarker Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            WellmarkerBio Receives Approval for Phase I Clinical Trial from the Australian Therapeutic Goods Administratio...

                            Details : Wellmarker has received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer.

                            Brand Name : WM-S1-030

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2021

                            Lead Product(s) : WM-S1-030

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Wellmarker Bio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting

                            Details : The upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting showcases a pre-clinical study investigating the effect of KBP-5074 on aldosterone-mediated renal injury in the uninephrectomized SD rat CKD model.

                            Brand Name : KBP-5074

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 22, 2020

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KBP Biosciences Announces Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5...

                            Details : BLOCK-CKD is a Phase 2b, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of KBP-5074, on top of current therapy, in patients with Stage 3B/4 CKD and uncontrolled hypertens...

                            Brand Name : KBP-5074

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2020

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe CKD patients with and w...

                            Details : Single doses of 0.5 mg KBP-5074 were generally well tolerated in patients with severe CKD, with or without hemodialysis . Overall drug exposure was significantly lower in hemodialyzed patients vs. non-hemodialyzed patients.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 21, 2020

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Labcorp Drug Development

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074

                            Details : BLOCK CKD is a randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe CKD and uncontrolled hypertension.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 20, 2020

                            Lead Product(s) : KBP-5074

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Recipient : KBP Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth